AstraZeneca Pharma India Limited (ASTRAZEN.BO)
AstraZeneca Pharma India Limited operates in the Drug Manufacturers - Specialty & Generic industry of the Healthcare sector, headquartered in Bengaluru, KA, IN. The stock last traded at $7753.70, down 0.49% on the session, giving a market capitalisation of $193.94B. Its beta of 0.25 implies it has historically moved less than the broad market.
AstraZeneca Pharma India Limited (AZPIL) functions as a biopharmaceutical company, involved in the manufacturing, distribution, and marketing of pharmaceutical products both within India and internationally. Its extensive product lineup includes medications for cardiovascular and diabetes conditions, marketed under brand names such as Brilinta, Betaloc, Crestor, Forxiga, Imdur, Kombiglyze XR, Onglyza, Seloken XL, Xigduo XR, and QTERN. The company also offers respiratory treatments like Symbicort and FASENRA, along with a comprehensive array of oncology drugs, including LYNPARZA, Tagrisso, Iressa, Calquence, Casodex, Faslodex, Zoladex, and Arimidex. Beyond these, AZPIL provides therapies for renal, metabolic, and immunological disorders and delivers clinical trial services. Founded in 1979, this Bengaluru, India-based entity operates as a subsidiary of AstraZeneca Pharmaceuticals AB.
AstraZeneca Pharma India Limited is most often compared with the following Healthcare names: